The Hemoglobin, Albumin, Lymphocyte, and Platelet Score as a Prognostic Indicator for Dogs with Congestive Heart Failure Secondary to Myxomatous Mitral Valve Disease

Reliable prognostic indicators for congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD) in dogs are limited. The hemoglobin, albumin, lymphocyte, and platelet (HALP) score, a prognostic marker in humans, has not been evaluated in veterinary medicine. This study aimed to assess the HALP score's utility for predicting short-term mortality in dogs with CHF due to MMVD. This retrospective study included 54 small-breed dogs. The HALP score was calculated as: hemoglobin (g/L) × albumin (g/L) × lymphocytes (/L)/platelets (/L). Six-, nine-month, and one-year mortality were assessed. The HALP score was significantly higher in survivor groups. Receiver operating characteristic (ROC) analysis showed good predictive accuracy for six- and nine-month mortality (area under the curve > 0.7). A cut-off of 11.13 for six-month mortality yielded 44.44% sensitivity and 94.44% specificity. Kaplan-Meier analysis confirmed that a higher HALP score was associated with significantly longer survival. The HALP score appears to be a valuable, novel prognostic indicator for short-term mortality in dogs with CHF due to MMVD.